

**Dkpharm Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 30 April 2025**

# Dkpharm Limited

## CONTENTS

	<b>Page</b>
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 11

**Dkpharm Limited**  
**DIRECTORS AND OTHER INFORMATION**

<b>Directors</b>	Damian Kissane Andrew Kissane
<b>Company Secretary</b>	Andrew Kissane
<b>Company Number</b>	462052
<b>Registered Office and Business Address</b>	Fethard Pharmacy Main Street Fethard on Sea Co. Wexford
<b>Accountants</b>	Dains Ireland Chartered Accountants 38 Main Street Swords Co. Dublin
<b>Bankers</b>	AIB 25 Main Street Killarney Co. Kerry
<b>Solicitors</b>	Frank Mulvey Solicitors Castle Buildings Friary Road Naas Co. Kildare

# Dkpharm Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Statement of Changes in Equity and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Dains Ireland, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

### Signed on behalf of the board

---

**Andrew Kissane**  
Director

**26 January 2026**

---

**Damian Kissane**  
Director

**26 January 2026**

**Dkpharm Limited**  
**BALANCE SHEET**

as at 30 April 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Tangible assets	5	<u>289,933</u>	<u>284,784</u>
<b>Current Assets</b>			
Stocks	6	124,289	91,193
Debtors	7	176,346	169,702
Cash and cash equivalents		<u>253,498</u>	<u>420,935</u>
		<u>554,133</u>	<u>681,830</u>
<b>Creditors: amounts falling due within one year</b>	8	<u>(96,410)</u>	<u>(86,017)</u>
<b>Net Current Assets</b>		<u>457,723</u>	<u>595,813</u>
<b>Total Assets less Current Liabilities</b>		<u>747,656</u>	<u>880,597</u>
<b>Creditors:</b>			
amounts falling due after more than one year	9	<u>(974)</u>	<u>(1,949)</u>
<b>Net Assets</b>		<u><u>746,682</u></u>	<u><u>878,648</u></u>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		1	1
Retained earnings		<u>746,681</u>	<u>878,647</u>
<b>Equity attributable to owners of the company</b>		<u><u>746,682</u></u>	<u><u>878,648</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Dkpharm Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 26 January 2026 and signed on its behalf by:**

\_\_\_\_\_  
**Andrew Kissane**  
 Director

\_\_\_\_\_  
**Damian Kissane**  
 Director

**Dkpharm Limited**  
**STATEMENT OF CHANGES IN EQUITY**  
as at 30 April 2025

	<b>Called up share capital €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 May 2023</b>	1	930,818	930,819
Loss for the financial year	-	(52,171)	(52,171)
<b>At 30 April 2024</b>	1	878,647	878,648
Loss for the financial year	-	(131,966)	(131,966)
<b>At 30 April 2025</b>	<b>1</b>	<b>746,681</b>	<b>746,682</b>

# Dkpharm Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 1. General Information

Dkpharm Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 462052. The registered office of the company is Fethard Pharmacy, Main Street, Fethard on Sea, Co. Wexford which is also the principal place of business of the company. The principal activity of the company during the period was a retail pharmaceutical chemist, the dispensing of medicines and all related and associated activities. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax. Turnover is recognised at point of sale. HSE drug scheme income is accrued as necessary.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Freehold property	-	Nil
Fixtures, fittings and equipment	-	12.5% Straight Line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Income Statement.

#### Leasing

Rentals payable under operating leases are dealt with in the Income Statement as incurred over the period of the rental agreement.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

**Dkpharm Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

**Trade and other debtors**

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

**Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

**Borrowing costs**

Borrowing costs are capitalised as part of the cost of a qualifying asset when it is probable that they will result in future economic benefits to the enterprise and the costs can be measured reliably. Other borrowing costs are recognised as an expense in the period in which they are incurred

**Trade and other creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

**Employee benefits**

The company provides a range of short term benefits to certain employees including holiday pay and this is recognised when the service is provided.

**Taxation and deferred taxation**

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Pensions**

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. Annual contributions payable to the company's pension scheme are charged to the Income Statement in the period to which they relate.

**Ordinary share capital**

The ordinary share capital of the company is presented as equity.

<b>3. Operating loss</b>	<b>2025</b>	<b>2024</b>
	€	€
<b>Operating loss is stated after charging:</b>		
Depreciation of tangible assets	<b>1,487</b>	<b>916</b>
	<u>          </u>	<u>          </u>

**4. Employees**

The average monthly number of employees, including directors, during the financial year was 6, (2024 - 5).

**Dkpharm Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

**5. Tangible assets**

	Freehold property €	Fixtures, fittings and equipment €	Total €
<b>Cost</b>			
At 1 May 2024	280,188	75,790	355,978
Additions	-	6,636	6,636
	<u>280,188</u>	<u>82,426</u>	<u>362,614</u>
At 30 April 2025	280,188	82,426	362,614
<b>Depreciation</b>			
At 1 May 2024	-	71,194	71,194
Charge for the financial year	-	1,487	1,487
	<u>-</u>	<u>72,681</u>	<u>72,681</u>
At 30 April 2025	-	72,681	72,681
<b>Net book value</b>			
At 30 April 2025	<u><b>280,188</b></u>	<u><b>9,745</b></u>	<u><b>289,933</b></u>
At 30 April 2024	<u>280,188</u>	<u>4,596</u>	<u>284,784</u>

<b>6. Stocks</b>	<b>2025</b>	<b>2024</b>
	€	€
Finished goods and goods for resale	<u><b>124,289</b></u>	<u>91,193</u>

<b>7. Debtors</b>	<b>2025</b>	<b>2024</b>
	€	€
Trade debtors	<b>62,399</b>	60,011
Other debtors	<b>12,067</b>	4,234
Directors' current accounts (Note 13)	<b>42,571</b>	16,936
Taxation	<b>59,309</b>	88,521
	<u><b>176,346</b></u>	<u>169,702</u>

Amounts owed by directors are unsecured, interest free and repayable on demand.

<b>8. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due within one year</b>	€	€
Net obligations under finance leases and hire purchase contracts	<b>975</b>	975
Trade creditors	<b>67,303</b>	63,118
Taxation	<b>17,416</b>	8,063
Directors' current accounts (Note 13)	<b>5,000</b>	8,000
Other creditors	<b>216</b>	661
Accruals	<b>5,500</b>	5,200
	<u><b>96,410</b></u>	<u>86,017</u>

Amounts owed to directors are unsecured, interest free and repayable on demand.

**Dkpharm Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

<b>9. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due after more than one year</b>	<b>€</b>	<b>€</b>
Finance leases and hire purchase contracts	<b>974</b>	1,949
	<u>          </u>	<u>          </u>
<b>Net obligations under finance leases and hire purchase contracts</b>		
Repayable within one year	<b>975</b>	975
Repayable between one and five years	<b>974</b>	1,949
	<u>          </u>	<u>          </u>
	<b>1,949</b>	2,924
	<u>          </u>	<u>          </u>
<b>10. Pension costs - defined contribution</b>		
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Pension costs amounted to €269,500 (2024 - €185,000).		
<b>11. Income Statement</b>		
	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
At 1 May 2024	<b>878,647</b>	930,818
Loss for the financial year	<b>(131,966)</b>	(52,171)
	<u>          </u>	<u>          </u>
At 30 April 2025	<b>746,681</b>	878,647
	<u>          </u>	<u>          </u>
<b>12. Financial commitments</b>		
Total future minimum lease payments under non-cancellable operating leases are as follows:		
	<b>Land and Buildings</b>	
	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
<b>Due:</b>		
Within one year	<b>14,508</b>	14,508
Between one and five years	<b>29,016</b>	43,524
	<u>          </u>	<u>          </u>
	<b>43,524</b>	58,032
	<u>          </u>	<u>          </u>
The lease is due to expire on 30 April 2028.		
<b>13. Directors' remuneration and transactions</b>	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
<b>Directors' remuneration</b>		
Remuneration	<b>90,156</b>	132,601
Pension contributions	<b>54,000</b>	185,000
	<u>          </u>	<u>          </u>
	<b>144,156</b>	317,601
	<u>          </u>	<u>          </u>

**Dkpharm Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

As permitted by the Companies Act 2014 the following interest free loans were made to the directors:

	Balance at 30/04/25 €	Advances €	Repayments €	Amounts waived in year €	Balance at 30/04/24 €
Damian Kissane	<u>42,571</u>	<u>100,723</u>	<u>(75,088)</u>	<u>-</u>	<u>16,936</u>

Value of the above arrangements with directors expressed as a percentage of the company's net assets;

	01/05/24 1.93%	30/04/25 5.70%	01/05/23 17.75%	30/04/24 1.93%
Damian Kissane	<u>1.93%</u>	<u>5.70%</u>	<u>17.75%</u>	<u>1.93%</u>

The following amounts are repayable to the directors:

	2025 €	2024 €
Andrew Kissane	<u>5,000</u>	<u>8,000</u>

Net balances due (to) the directors:

	2025 €	2024 €
Damian Kissane	<u>42,571</u>	<u>16,936</u>
Andrew Kissane	<u>(5,000)</u>	<u>(8,000)</u>
	<u>37,571</u>	<u>8,936</u>

**14. Controlling interest**

The Director, Damian Kissane, has controlling interest over the company as he owns 100% of the share capital.

**15. Post-Balance Sheet Events**

There have been no significant events affecting the company since the financial year-end which require disclosure in the financial statements.

**16. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 26 January 2026.